What changed
STERIS posted Q2 FY27 adjusted EPS of $2.94, beating the $2.67 consensus by $0.27 (+10.1%). Revenue came in at $1,589M, up 8.8% YoY, with constant currency organic growth of 8%. Management raised FY27 adjusted EPS guidance to $11.35–$11.55 from $11.10–$11.30, citing solid underlying performance plus the benefit of tariff refunds received year-to-date (~$0.18), while FY27 revenue growth guidance held at 7–8%. Life Sciences drove the beat, with revenue up 18% on 53% capital equipment growth, prompting the company to raise full-year segment expectations.
Why it matters
STERIS posted Q2 FY27 adjusted EPS of $2.94, beating the $2.67 consensus by $0.27 (+10.1%). Revenue came in at $1,589M, up 8.8% YoY, with constant currency organic growth of 8%. Management raised FY27